Back to top
more

Teleflex (TFX)

(Delayed Data from NYSE)

$116.06 USD

116.06
512,581

+0.17 (0.15%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $116.03 -0.03 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Chemed's Roto-Rooter & VITAS Robust, Acuity Mix Shift Weak

by Zacks Equity Research

Chemed's (CHE) VITAS shows higher adoption via an expanded average daily census. Also, the Roto-Rooter's business grows on the back of strong core plumbing and drain cleaning service segments.

Zacks Equity Research

Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.

Zacks Equity Research

Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand

by Zacks Equity Research

The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.

Zacks Equity Research

Here's Why You Should Hold Onto Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors' trust continues to be high in Neogen (NEO), thanks to strength in its Food Safety and Genomic businesses.

Zacks Equity Research

TFX or STE: Which is a Better Investment Pick Right Now?

by Zacks Equity Research

STERIS (STE) scores higher than Teleflex (TFX) when it comes to valuation and one-year price performance.

Zacks Equity Research

Illumina (ILMN) Grows on Innovation & International Growth

by Zacks Equity Research

Illumina (ILMN) is benefiting from sturdy demand for sequencing and array systems as well as consumables and services.

Zacks Equity Research

NuVasive (NUVA) Launches Pulse Integrated Technology Platform

by Zacks Equity Research

The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.

Zacks Equity Research

Boston Scientific's Global Growth Robust Amid Currency Woe

by Zacks Equity Research

Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.

Zacks Equity Research

Medtronic Releases Positive Results of LATERAL Clinical Trial

by Zacks Equity Research

Positive outcomes prove to be a major breakthrough for Medtronic (MDT) in the growing field of ventricular assist devices.

Zacks Equity Research

ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite

by Zacks Equity Research

ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.

Zacks Equity Research

Integra Partners AI-Driven Data Analytics Firm in Wound Care

by Zacks Equity Research

Integra LifeSciences (IART) expects its partnership with Tissue Analytics to be perfectly strategic as the latter's software solutions automatically derive high quality data from clinical pictures.

Zacks Equity Research

Phibro Animal Sees Crucial Progress in ASF Vaccine Development

by Zacks Equity Research

The identification of a group of peptides and proteins is a remarkable step toward Phibro's (PAHC) development of a solution for ASF.

Zacks Equity Research

Fresenius Set for Global Expansion of Research Activities

by Zacks Equity Research

Fresenius Medical Care (FMS) aims to expand the scope of its clinical research activities through an integration move.

Zacks Equity Research

Illumina (ILMN) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Illumina (ILMN) gains from expansion of its product portfolio and strategic partnership.

Zacks Equity Research

CVS Health Banks on Aetna Prospects, Omnicare May Disappoint

by Zacks Equity Research

CVS Health's (CVS) Aetna integration synergies bode well for the stock.

Zacks Equity Research

Boston Scientific to Sell Bead Suit, Make Way for BTG Buyout

by Zacks Equity Research

The sale of oncology bead products by Boston Scientific (BSX) is expected to be among the last steps undertaken by the company to obtain Federal Trade Commission's approval for BTG buyout.

Zacks Equity Research

Here's Why CVS Health (CVS) Should Be in Your Portfolio

by Zacks Equity Research

Investors' trust continues to be high in CVS Health (CVS), thanks to strength in its PBM business.

Zacks Equity Research

Here's Why Chemed (CHE) Should Remain in Your Portfolio Now

by Zacks Equity Research

Investors' trust in Chemed (CHE) continues to be high, banking on its sturdy segmental performance.

Zacks Equity Research

Edwards Lifesciences Recalls Heart Device on Balloon Rupture

by Zacks Equity Research

Shares of Edwards Lifesciences (EW) decline post product recall news.

Zacks Equity Research

Teleflex (TFX) Shares Down on Respiratory Care Product Recall

by Zacks Equity Research

Teleflex (TFX) issued a statement saying consumers who own the tampered product should immediately discontinue use and return all affected products.

Zacks Equity Research

Hill-Rom (HRC) Gains on Product Launch, Prudent Buyouts

by Zacks Equity Research

The contribution from new products is substantial to bolster top-line growth during the first half of fiscal 2019 at Hill-Rom (HRC).

Zacks Equity Research

Here's Why You Should Hold GNC Holdings (GNC) Stock for Now

by Zacks Equity Research

GNC Holdings (GNC) continues to witness investors' confidence, courtesy of a few positive factors like strategic new partnerships.

Zacks Equity Research

Bruker (BRKR) Launches the MALDI Biotyper Sirius System

by Zacks Equity Research

The launch is a milestone for Bruker (BRKR) in assay research and clinical studies for fast antibiotic-resistance testing.

Zacks Equity Research

Teleflex (TFX) Hits New 52-Week High on Solid Growth Drivers

by Zacks Equity Research

Teleflex (TFX) gains from acquisition of NeoTract and Vascular Solutions.

Zacks Equity Research

Here's Why You Should Invest in Teleflex (TFX) Stock Now

by Zacks Equity Research

Teleflex (TFX) benefits from rising investors' confidence, courtesy of the NeoTract acquisition.